Status:
COMPLETED
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
American Diabetes Association
Conditions:
Overweight and Obesity
Eating Behavior
Eligibility:
All Genders
18-35 years
Phase:
PHASE3
Brief Summary
The current project applies an integrative three-prong approach to investigate the potential of the dopamine D2 receptor (DRD2) agonist bromocriptine to: 1) increase homeostatic satiation signaling, 2...
Detailed Description
Twenty-nine million Americans have diagnosed type 2 diabetes (T2DM), with fewer than half able to meet treatment goals and considerably more are at risk for development of T2DM. Implementation of heal...
Eligibility Criteria
Inclusion
- Baseline BMI between 25 and 35
Exclusion
- Individuals with current fMRI contraindications (e.g., metal implants, braces)
- Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder)
- Habitual use of cigarettes or illicit drugs
- Pregnancy or breastfeeding
- Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke)
- Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks
- Do not consume dairy
- Allergy to bromocriptine, dairy, and nuts
Key Trial Info
Start Date :
September 19 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2019
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT05405244
Start Date
September 19 2017
End Date
September 19 2019
Last Update
September 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States, 27599